GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
Open accessPublished version of a preprint
Abstract
Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq). Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) was explored. Results: Between December 2015 and May 2019, 195 patients (95%) had enough tissue for RNA-seq; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% versus 33%, respectively (P = 0.02). In patients with basal-like tumors treated with modified FOLFIRINOX (n = 22), the progression rate was 60% compared with 15% in classical PDAC (P = 0.0002). Median OS in the intention-to-treat population (n = 195) was 9.3 months for classical versus 5.9 months for basal-like PDAC (HR, 0.47; 95% confidence interval, 0.32–0.69; P = 0.0001). GATA6 expression by RNA-seq highly correlated with the classifier (P < 0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariate analysis, GATA6 expression was prognostic (P = 0.02). In exploratory analyses, basal-like tumors, could be identified by keratin 5, were more hypoxic and enriched for a T-cell–inflamed gene expression signature. Conclusions: The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression. See related commentary by Collisson, p. 4715
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype.
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556 · see citing works
The control of the false discovery rate in multiple testing under dependency
Benjamini, Y., & Yekutieli, D. (2001) · The Annals of Statistics · doi:10.1214/aos/1013699998 · Cited by 10,490 · see citing works
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908 · see citing works
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 6× · see citing works
“9 (median, range) 1832 (1-371847) 1124 (1-71956) 0.”
BackgroundInfluentialScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203 · see citing works
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · see citing works
Self-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · see citing works
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194 · see citing works
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · see citing works
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092 · see citing works
Self-citationMolecular subtypes of pancreatic cancer
Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892 · see citing works
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M., Connor, A. A., Denroche, R. E., Grant, R. C., McLeod, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0566-9 · Cited by 669 · see citing works
Self-citationVariation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 632 · see citing works
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618 · see citing works
Self-citationDouillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · see citing works
Expression of luminal and basal cytokeratins in human breast carcinoma
El‐Rehim, D. M. A., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594 · see citing works
Trujillo, J., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 392 · see citing works
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 285 · see citing works
Self-citationMartinelli, P., Pau, E. C. D. S., Cox, T. F., Sáinz, B., Dusetti, N., Greenhalf, W., Rinaldi, L., Costello, E., Ghaneh, P., Malats, N., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311256 · Cited by 268 · see citing works
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A. X. W., Chan‐Seng‐Yue, M., Wilson, G. W., Grant, R. C., Merico, D., Lungu, I. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 231 · see citing works
Self-citationDiagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 228 · see citing works
Hayashi, A., Fan, J., Chen, R., Ho, Y.-J., Makohon-Moore, A. P., Lecomte, N., Zhong, Y., Hong, J., Huang, J., Sakamoto, H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0010-1 · Cited by 204 · see citing works
Shi, Z., Lee, K., Yang, D.-P., Amin, S., Verma, N., Li, Q. V., Zhu, Z., Soh, C., Kumar, R., Evans, T., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.01.001 · Cited by 150 · see citing works
Kalimuthu, S. N., Wilson, G. W., Grant, R. C., Seto, M., O'Kane, G. M., Vajpeyi, R., Notta, F., Gallinger, S., & Chetty, R. (2019) · Gut · doi:10.1136/gutjnl-2019-318217 · Cited by 134 · see citing works
Self-citationTempero, M. A., Cutsem, E. V., Sigal, D. S., Oh, D., Fazio, N., Macarulla, T. M., Hitre, E., Hammel, P. R., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.638 · Cited by 125 · see citing works
Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer
Roa‐Peña, L., Leiton, C. V., Babu, S., Pan, C., Vanner, E. A., Akalin, A., Bandovic, J., Moffitt, R. A., Shroyer, K. R., & Escobar‐Hoyos, L. F. (2019) · Scientific Reports · doi:10.1038/s41598-019-47519-4 · Cited by 85 · see citing works
De novo compartment deconvolution and weight estimation of tumor samples using DECODER
Peng, X. L., Moffitt, R. A., Torphy, R. J., Volmar, K. E., & Yeh, J. J. (2019) · Nature Communications · doi:10.1038/s41467-019-12517-7 · Cited by 56 · see citing works
Khanom, R., Sakamoto, K., Pal, S. K., Shimada, Y., Morita, K., Omura, K., Miki, Y., & Yamaguchi, A. (2012) · PubMed · doi:10.14670/hh-27.949 · Cited by 37 · see citing works
Flagged first, then by citations
2 of the 39 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Raghavan, S., Winter, P. S., Navia, A. W., Williams, H. L., DenAdel, A., Lowder, K. E., Galvez-Reyes, J., Kalekar, R. L., Mulugeta, N., Kapner, K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.017 · Cited by 592 · see citing works
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578 · see citing works
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 481 · see citing works
Spatially confined sub-tumor microenvironments in pancreatic cancer
Grünwald, B. T., Devisme, A., Andrieux, G., Vyas, F., Aliar, K., McCloskey, C. W., Macklin, A., Jang, G. H., Denroche, R., Romero, J. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.022 · Cited by 433 · see citing works
Self-citationTherapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 427 · see citing works
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369 · see citing works
Self-citationWerba, G., Weissinger, D., Kawaler, E. A., Zhao, E., Kalfakakou, D., Dhara, S., Wang, L., Lim, H. B., Oh, G., Jing, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36296-4 · Cited by 292 · see citing works
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 276 · see citing works
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
BackgroundTranslational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 249 · see citing works
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211 · see citing works
The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 133 · see citing works
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L. B., Huang, L., Akshinthala, D., Perea, S., González, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 128 · see citing works
Miyabayashi, K., Baker, L. A., Deschênes, A., Traub, B., Caligiuri, G., Plenker, D., Alagesan, B., Belleau, P., Li, S., Kendall, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0133 · Cited by 125 · see citing works
Self-citationQuPath: The global impact of an open source digital pathology system
Humphries, M. P., Maxwell, P., & Salto‐Tellez, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.022 · Cited by 124 · see citing works
Yousuf, S., Qiu, M., von Voithenberg, L. V., Hulkkonen, J., Mačinković, I., Schulz, A. R., Hartmann, D., Mueller, F., Mijatovic, M., Ibberson, D., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.036 · Cited by 116 · see citing works
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 114 · see citing works
Ruivo, C. F., Bastos, N., Adem, B., Batista, I. A., Durães, C., Melo, C. A., Castaldo, S. A., Campos-Laborie, F. J., Moutinho-Ribeiro, P., Morão, B., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324994 · Cited by 98 · see citing works
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 99 · see citing works
Leiphrakpam, P. D., Chowdhury, S., Zhang, M. H., Bajaj, V., Dhir, M., & Are, C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01183-2 · Cited by 99 · see citing works
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 87 · see citing works
Picard, F. S. R., Lutz, V., Brichkina, A. I., Neuhaus, F., Ruckenbrod, T., Hupfer, A., Raifer, H., Klein, M., Bopp, T., Pfefferle, P. I., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327855 · Cited by 86 · see citing works
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Singhal, A., Styers, H. C., Rub, J., Li, Z., Torborg, S. R., Kim, J. Y., Grbovic-Huezo, O., Feng, H., Tarcan, Z. C., Sahin Ozkan, H., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0740 · Cited by 84 · see citing works
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
Duan, X., Zhang, T., Feng, L., de Silva, N., Greenspun, B. C., Wang, X., Moyer, J. E., Martin, M. L., Chandwani, R., Elemento, O., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.011 · Cited by 84 · see citing works
Li, Y., Tang, S., Shi, X., Lv, J., Wu, X., Zhang, Y., Wang, H., He, J., Zhu, Y., Ju, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101162 · Cited by 79 · see citing works
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 85 · see citing works
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 78 · see citing works
Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0672 · Cited by 76 · see citing works
Saillard, C., Delecourt, F., Schmauch, B., Moindrot, O., Svrcek, M., Bardier–Dupas, A., Emile, J., Ayadi, M., Rebours, V., de Mestier, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39026-y · Cited by 74 · see citing works
Qiang, L., Hoffman, M. T., Ali, L. R., Castillo, J. I., Kageler, L., Temesgen, A., Lenehan, P., Wang, S. J., Bello, E., Cardot-Ruffino, V., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.038 · Cited by 75 · see citing works
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01287-7 · Cited by 75 · see citing works
Mechanisms of PDAC subtype heterogeneity and therapy response
Espinet, E., Klein, L., Puré, E., & Singh, S. K. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.005 · Cited by 70 · see citing works
Law, H. C.-H., Lagundžin, D., Clement, E. J., Qiao, F., Wagner, Z. S., Krieger, K. L., Costanzo-Garvey, D. L., Caffrey, T. C., Grem, J. L., DiMaio, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1496 · Cited by 71 · see citing works
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 68 · see citing works
Wörmann, S. M., Zhang, A. X. W., Thege, F. I., Cowan, R. W., Rupani, D. N., Wang, R., Manning, S. L., Gates, C., Wu, W.-S., Levin-Klein, R., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00268-8 · Cited by 67 · see citing works
Self-citationPersister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 67 · see citing works
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 66 · see citing works
Beutel, A. K., Schütte, L. D., Scheible, J., Roger, É., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., et al. (2021) · Cancers · doi:10.3390/cancers13112539 · Cited by 65 · see citing works
Sans, M., Makino, Y., Min, J., Rajapakshe, K., Yip-Schneider, M., Schmidt, C. M., Hurd, M. W., Burks, J. K., Gomez, J. A., Thege, F. I., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1200 · Cited by 64 · see citing works
Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma
Chijimatsu, R., Kobayashi, S., Takeda, Y., Kitakaze, M., Tatekawa, S., Arao, Y., Nakayama, M., Tachibana, N., Saito, T., Ennishi, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104659 · Cited by 63 · see citing works
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
Espona‐Fiedler, M., Patthey, C., Lindblad, S., Sarró, I., & Öhlund, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116492 · Cited by 59 · see citing works
Topham, J. T., Karasinska, J. M., Lee, M. K. C., Csizmók, V., Williamson, L., Jang, G. H., Denroche, R. E., Tsang, E. S., Kalloger, S. E., Wong, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2831 · Cited by 54 · see citing works
Self-citationPCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
Rademaker, G., Hernandez, G. A., Seo, Y., Dahal, S., Miller‐Phillips, L., Li, A. L., Peng, X. L., Luan, C., Qiu, L., Liegeois, M. A., et al. (2025) · Nature · doi:10.1038/s41586-025-09017-8 · Cited by 54 · see citing works
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 50 · see citing works
Stossel, C., Raitses‐Gurevich, M., Atias, D., Beller, T., Gorman, Y. G., Halperin, S., Peer, E., Denroche, R. E., Zhang, A. X. W., Notta, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0412 · Cited by 51 · see citing works
Self-citationEyres, M., Lanfredini, S., Xu, H., Burns, A., Blake, A., Willenbrock, F. W., Goldin, R. D., Hughes, D. L., Hughes, S. L., Thapa, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.044 · Cited by 50 · see citing works
Philip, P. A., Sahai, V., Bahary, N., Mahipal, A., Kasi, A., Lima, C. M. S. R., Alistar, A. T., Oberstein, P. E., Golan, T., Metges, J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02659 · Cited by 49 · see citing works
Duan, K., Jang, G.-H., Grant, R. C., Wilson, J. M., Notta, F., O'Kane, G. M., Knox, J. J., Gallinger, S., & Fischer, S. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94544-3 · Cited by 48 · see citing works
Self-citationHosen, S. M. Z., Uddin, M. N., Xu, Z., Buckley, B. J., Perera, C. J., Pang, T., Mekapogu, A. R., Moni, M. A., Notta, F., Gallinger, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060957 · Cited by 50 · see citing works
Self-citationNext-generation therapies for pancreatic cancer
Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 47 · see citing works
Klein, L., Tu, M., Krebs, N., Urbach, L., Grimm, D. T., Latif, M. U., Penz, F., Blandau, A., Wu, X., Samuel, R. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55330-7 · Cited by 46 · see citing works
Self-citationDatta, J., Bianchi, A., Silva, I. D. C., Deshpande, N., Cao, L., Mehra, S., Singh, S. P., Rafie, C. I., Sun, X., Chen, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02368-w · Cited by 45 · see citing works
Self-citationLiu, Z., Hayashi, H., Matsumura, K., Ogata, Y., Sato, H., Shiraishi, Y., Uemura, N., Miyata, T., Higashi, T., Nakagawa, S., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02106-9 · Cited by 45 · see citing works
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
Garajová, I., Peroni, M., Gelsomino, F., & Leonardi, F. (2023) · Current Oncology · doi:10.3390/curroncol30110694 · Cited by 48 · see citing works
Evolutionary fingerprints of epithelial-to-mesenchymal transition
Perelli, L., Zhang, L., Mangiameli, S. M., Giannese, F., Mahadevan, K. K., Peng, F., Citron, F., Khan, H., Le, C. N., Gurreri, E., et al. (2025) · Nature · doi:10.1038/s41586-025-08671-2 · Cited by 48 · see citing works
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Gómez‐España, M. A., Montés, A. F., García‐Carbonero, R., Macarulla, T. M., Maurel, J., Martín, Á., Pazo-Cid, R., Vera, R., Carrato, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02573-1 · Cited by 45 · see citing works
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 45 · see citing works
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 47 · see citing works
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini, L., Pasini, D., Fang, R., Delfino, P., Filippini, D., Neander, C., Vicentini, C., Fiorini, E., Lupo, F., D’Agosto, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54975-8 · Cited by 43 · see citing works
Salinas-Miranda, E., Deniffel, D., Dong, X., Healy, G. M., Khalvati, F., O'Kane, G. M., Knox, J. J., Bathe, O. F., Baracos, V. E., Gallinger, S., et al. (2021) · European Radiology · doi:10.1007/s00330-021-07899-6 · Cited by 43 · see citing works
Self-citationClinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 42 · see citing works
Topham, J. T., Tsang, E. S., Karasinska, J. M., Metcalfe, A. L., Ali, H., Kalloger, S. E., Csizmók, V., Williamson, L., Titmuss, E., Nielsen, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33718-7 · Cited by 41 · see citing works
Self-citationKnox, J. J., O'Kane, G. M., King, D. A., Laheru, D. A., Habowski, A. N., Yu, K. H., Perez, K. J., Aguirre, A. J., Coyne, Z. L., Harvey, H. M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00436 · Cited by 41 · see citing works
Self-citationA p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zhong, Z., Harmston, N., Wood, K. C., Madan, B., & Virshup, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156305 · Cited by 39 · see citing works
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 38 · see citing works
Fraunhoffer, N. A., Hammel, P. R., Conroy, T., Nicolle, R., Bachet, J., Harlé, A., Rebours, V., Turpin, A., Abdelghani, M. B., Mitry, E., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.010 · Cited by 39 · see citing works
Self-citationPancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
Pompella, L., Tirino, G., Pappalardo, A., Caterino, M., Ventriglia, A., Nacca, V., Orditura, M., Ciardiello, F., & Vita, F. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082814 · Cited by 38 · see citing works
Ghanem, I., Lora, D., Herradón, N., de Velasco, G., Carretero-González, A., Varas, M. Á. J., de Parga, P. V., & Feliú, J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100485 · Cited by 39 · see citing works
Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
Saiki, Y., Jiang, C., Ohmuraya, M., & Furukawa, T. (2021) · Cancers · doi:10.3390/cancers14010071 · Cited by 38 · see citing works
de Andrés, M. P., Jackson, R., Felipe‐Abrio, I., Zagorac, S., Pilarsky, C. P., Schlitter, A. M., de Villarreal, J. M., Jang, G. H., Costello, E., Gallinger, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325803 · Cited by 36 · see citing works
Self-citationWhole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Knox, J. J., Jang, G. H., Grant, R. C., Zhang, A. X. W., Ma, L. X., Elimova, E. C., Jang, R., Moore, M. J., Biagi, J. J., Tehfe, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60808-z · Cited by 38 · see citing works
Self-citationChakrabarti, S., Kamgar, M., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14112588 · Cited by 36 · see citing works
Decoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 35 · see citing works
Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility
Oketch, D. J. A., Giulietti, M., & Piva, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010391 · Cited by 35 · see citing works
Nakazawa, Y., Miyano, M., Tsukamoto, S., Kogai, H., Yamamoto, A., Iso, K., Inoue, S., Yamane, Y., Yabe, Y., Umihara, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46167-1 · Cited by 36 · see citing works
George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 35 · see citing works
Perera, S., Jang, G. H., Wang, Y., Kelly, D., Allen, M. J., Zhang, A. X. W., Denroche, R. E., Dodd, A., Ramotar, S., Hutchinson, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2576 · Cited by 35 · see citing works
Self-citationMoving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34 · see citing works
Self-citationCarpenter, E. S., Kadiyala, P., Elhossiny, A. M., Kemp, S. B., Li, J., Steele, N. G., Nicolle, R., Nwosu, Z. C., Freeman, J., Dai, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1421 · Cited by 32 · see citing works
Jain, P., Dvorkin‐Gheva, A., Mollen, E., Malbeteau, L., Xie, M. H., Jessa, F., Dhavarasa, P., Chung, S., Brown, K. R., Jang, G. H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf7114 · Cited by 32 · see citing works
Self-citationDardare, J., Witz, A., Merlin, J., Bochnakian, A., Toussaint, P., Gilson, P., & Harlé, A. (2021) · Pharmaceuticals · doi:10.3390/ph14080740 · Cited by 31 · see citing works
Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
Pappalardo, A., Giunta, E. F., Tirino, G., Pompella, L., Federico, P., Daniele, B., Vita, F. D., & Petrillo, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695627 · Cited by 32 · see citing works
Gene Targeting in Disease Networks
Weighill, D. A., Guebila, M. B., Glass, K., Platig, J., Yeh, J. J., & Quackenbush, J. F. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.649942 · Cited by 30 · see citing works
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30 · see citing works
Epigenetic Clock and Circadian Rhythms in Stem Cell Aging and Rejuvenation
Samoilova, E. M., Викторович, Б. В., Ekusheva, E. V., Zhang, C., Troitskiy, A. V., & Baklaushev, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111050 · Cited by 32 · see citing works
Ruta, V., Naro, C., Pieraccioli, M., Leccese, A., Archibugi, L., Cesari, E., Panzeri, V., Allgöwer, C., Arcidiacono, P. G., Falconi, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101411 · Cited by 29 · see citing works
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28 · see citing works
Kokumai, T., Omori, Y., Ishida, M., Ohtsuka, H., Mizuma, M., Nakagawa, K., Maeda, C., Ono, Y., Mizukami, Y., Miura, S., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100102 · Cited by 28 · see citing works
Ubhi, T., Zaslaver, O., Quaile, A. T., Plenker, D., Cao, P. M., Pham, N., Békési, A., Jang, G.-H., O'Kane, G. M., Notta, F., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00742-z · Cited by 27 · see citing works
Self-citationROR2 Regulates Cellular Plasticity in Pancreatic Neoplasia and Adenocarcinoma
Benitz, S., Steep, A., Nasser, M. M., Preall, J. B., Mahajan, U. M., McQuithey, H., Loveless, I. M., Davis, E. T., Wen, H.-J., Long, D. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0137 · Cited by 27 · see citing works
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 26 · see citing works
Maddipati, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191943 · Cited by 26 · see citing works
Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Gao, C., Wisniewski, L., Liu, Y., Staal, B., Beddows, I., Plenker, D., Aldakkak, M., Hall, J., Barnett, D., Gouda, M. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2475 · Cited by 26 · see citing works
Ecker, B. L., Tao, A. J., Janssen, Q. P., Walch, H. S., Court, C. M., Balachandran, V. P., Crane, C. H., D'Angelica, M. I., Drebin, J. A., Kingham, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3089 · Cited by 26 · see citing works
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma
Ma, L. X., Wang, Y., Espin‐Garcia, O., Allen, M. J., Jang, G. H., Zhang, A. X. W., Dodd, A., Ramotar, S., Hutchinson, S., Tehfe, M. A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02214-0 · Cited by 26 · see citing works
Self-citationNab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
Carrato, A., Pazo-Cid, R., Macarulla, T. M., Gallego-Plazas, J., Jiménez‐Fonseca, P., Rivera, F., Cano, M. T., Rodríguez-Garrote, M., Pericay, C., Alés, I., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2300144 · Cited by 26 · see citing works
MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages
Kato, H., Tateishi, K., Fujiwara, H., Nakatsuka, T., Yamamoto, K., Kudo, Y., Hayakawa, Y., Nakagawa, H., Tanaka, Y., Ijichi, H., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.254 · Cited by 25 · see citing works
Torre-Healy, L. A., Kawalerski, R. R., Oh, K., Chrastecka, L., Peng, X. L., Aguirre, A. J., Rashid, N. U., Yeh, J. J., & Moffitt, R. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04461-6 · Cited by 25 · see citing works
Leary, J. R., Xu, Y., Morrison, A. B., Jin, C., Shen, E. C., Kuhlers, P. C., Su, Y., Rashid, N. U., Yeh, J. J., & Peng, X. L. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad449 · Cited by 25 · see citing works
PDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24 · see citing works
Nimgaonkar, V. U., Krishna, V., Krishna, V., Tiu, E., Joshi, A., Vrabac, D., Bhambhvani, H. P., Smith, K., Johansen, J. S., Makawita, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101013 · Cited by 24 · see citing works
- Authors
- O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., Lam, B., Krzyzanowski, P. M., Lungu, I. M., Bartlett, J. M. S., Peralta, M., Vyas, F., Khokha, R., Biagi, J., Chadwick, D., Ramotar, S., Hutchinson, S., Dodd, A., Wilson, J. M., Notta, F., Zogopoulos, G., Gallinger, S., Knox, J. J., & Fischer, S. E.
- Affiliations
- 1Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
- Ontario Institute for Cancer Research (CA)
- University Health Network (CA)
- Research Institute of the McGill University Health Centre (CA)
- Kingston General Hospital (CA)
- ORCID
- Grünwald, Barbara T.
- Jang, Gun-Ho
- Grant, Robert C.
- Denroche, Robert E.
- Zhang, Amy
- Wang, Yifan
- Miller, Jessica K.
- Lam, Bernard
- Krzyzanowski, Paul M.
- Lungu, Ilinca M.
- Bartlett, John M.S.
- Peralta, Melanie
- Vyas, Foram
- Khokha, Rama
- Biagi, James
- Ramotar, Stephanie
- Hutchinson, Shawn
- Dodd, Anna
- Wilson, Julie M.
- Notta, Faiyaz
- Zogopoulos, George
- Knox, Jennifer J.
- Fischer, Sandra E.
- Venue
- Clinical Cancer Research
- Published
- 2020-03-10
- Volume
- 26
- Issue
- 18
- Pages
- 4901-4910
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3011562658
- Semantic Scholar
- d72ef3593540c2afcd56ffaaa1ecbdf174cca98b
- Cited by
- 352
- References
- 39
- Citations by year
- 2026: 54 · 2025: 58 · 2024: 58 · 2023: 60 · 2022: 48 · 2021: 56 · 2020: 16 · 2019: 1
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-06-13)
- Open access
- Licence
- other-oa
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Princess Margaret Cancer Foundation (ALTF 116-2018, DEU 1199182 FLF-P)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- GATA6, pancreatic ductal adenocarcinoma, basal-like subtype, classical subtype, cancer subtyping, chemoresistance, modified FOLFIRINOX, overall survival, prognostic factors, keratin 5, tumor hypoxia, COMPASS trial
- MeSH terms
- Irinotecan, Oxaliplatin, RNA-Seq, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Prospective Studies, Multicenter Studies as Topic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, GATA6 Transcription Factor, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
